Smith & Nephew Plc
23 January 2006
Smith & Nephew Redenominates Share Capital
23 January 2006
Smith & Nephew plc (LSE: SN, NYSE: SNN) announces today that further to previous
announcements the share capital of the company has been redenominated into US
dollars by way of a reduction in capital and subsequent issue and allotment of
new dollar ordinary shares. The redenomination of the share capital was
approved by shareholders on 12 December 2005 and Court approval for the
reduction was received on 18 January 2006. The redenomination has been
registered at Companies House.
The nominal value of each dollar denominated ordinary share is now 20 cents.
Following this redenomination, shareholders receive one new dollar denominated
ordinary share for each sterling ordinary share held. The new shares have the
same rights and restrictions as the previously issued sterling ordinary shares.
The rights and obligations of the company's American Depositary Shares (ADS),
which are listed on the New York Stock Exchange, are not affected by the
redenomination and each ADS will continue to represent 5 ordinary shares.
Application has been made to the UK Listing Authority and to the London Stock
Exchange for 940,690,200 new dollar ordinary shares, being the issued share
capital of the company at the close of business on Friday 20 January 2006, to be
admitted to the Official List and, following approval and admission, trading in
the new dollar shares commences today. The company's shares continue to be
quoted in sterling on the London Stock Exchange.
In addition, application has been made to the UK Listing Authority and to the
London Stock Exchange, and approval given, for 7,462,500 ordinary shares to be
blocklisted for admission to the Official List under the following schemes. The
shares, which will rank pari passu in all respects with the new dollar shares in
issue, will be not be allotted immediately but as and when required pursuant to
the rules of the company's share option plans.
1991 Overseas Employee Share Option Scheme - 27,500
International Employees Share Option Scheme - 1,000,000
1985 Executive Share Option Scheme - 85,000
1990 International Executive Share Option Scheme - 1,850,000
2001 US Share Option Scheme - 1,500,000
2001 UK Approved Share Option Scheme - 500,000
2001 UK Unapproved Share Option Scheme - 1,000,000
UK Employee Share Option Scheme - 1,500,000.
Enquiries
Paul Chambers Tel: +44 (0) 20 7401 7646
Smith & Nephew
Company Secretary
Liz Hewitt Tel: +44 (0) 20 7401 7646
Smith & Nephew
Group Director Corporate Affairs
About us
Smith & Nephew is a global medical technology business, specialising in
Orthopaedics, Endoscopy and Advanced Wound Management products. Smith & Nephew
is a global leader in arthroscopy and advanced wound management and is one of
the fastest growing global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people's lives. The company
prides itself on the strength of its relationships with its surgeons and
professional healthcare customers, with whom its name is synonymous with high
standards of performance, innovation and trust. The company has over 8,500
employees and operates in 33 countries around the world generating annual sales
of US$2.26 billion.
This information is provided by RNS
The company news service from the London Stock Exchange
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.